To: Board of Supervisors
From: Dr. Ori Tzvieli, Interim Health Services Director
Report Title: Purchase Order with Illumina, Inc.
☒Recommendation of the County Administrator ☐ Recommendation of Board Committee
RECOMMENDATIONS:
APPROVE and AUTHORIZE the Purchasing Agent, or designee, to execute on behalf of the Interim Health Services Director, 1) a purchase order with Illumina, Inc. in an amount not to exceed $165,119, 2) Terms and Conditions of Sale, and 3) Service Contract Terms and Limitations for the purchase of laboratory equipment and the provision of training, maintenance, and nucleic acid (DNA/RNA) sequencing services at Contra Costa Health’s Public Health Laboratory for four years following delivery and installation of the equipment.
FISCAL IMPACT:
Approval of this action will result in a one-time expenditure of up to $165,119 and will be funded by Enhanced Laboratory Capacity (ELC) Enhancing Detection Expansion funds.
BACKGROUND:
Approval of this action will allow for the purchase of an Illumina MiSeq i100 Plus System and four years additional service at the Contra Costa Public Health Laboratory. The MiSeq i100 Plus allows for a much faster processing time (three days down to one) than the current short-read sequencer and reduces staff hands-on time. The instrument will be used for more efficient and faster analysis of bacterial genetic sequences from patient specimens and retail meat samples.
This purchase is subject to the Illumina, Inc. Terms and Conditions of Sale which limits the liability of the seller or its suppliers for costs of procurement of substitute products or services, lost profits, data or business, or for any indirect, special, incidental, exemplary, consequential, or punitive damages of any kind. The County is required to indemnify and hold harmless the seller, its affiliates, their non-affiliate collaborators and development partners that contributed to the development of the Product, and their respective officers, directors, representatives and employees against any claims, liabilities, damages, fines, penalties, causes of action, and losses of any and every kind (including reasonable attorneys’ fees), including without limitation, personal injury or death claims, and infringement of a third party’s intellectual property rights. All disputes arising out of the agreement are to be resolved through confidential binding arbitration. This purchase is being justified via sole source.
CONSEQUENCE OF NEGATIVE ACTION:
If this action is not approved, use of the current, slower sequencing instrumentation will continue. Staff will continue with additional multi-step, hands-on processing time of specimens. Purchase of a new MiSeq i100 after June 2025, will cost the county additional funds and include additional installation fees due to expiration of discount offer.